



U.S. N. 09/833,407
Transmittal of IDS

#4 1514

04676.10503

RECEIVED
JAN 18 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Luchoomun *et al.*

Serial No.: 09/833,407

Art Unit: 1614

Filed: April 11, 2001

Examiner: Unknown

For: Compounds and Methods to Increase Plasma HDL Cholesterol Levels and Improved HDL Functionality

Assistant Commissioner for Patents
Box IDS
Washington, DC 20231

Information Disclosure Statement Transmittal

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed.

Please charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,


Clark G. Sullivan
Reg. No. 36,942

KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-2882 (Telephone)
404-572-5145 (Facsimile)

U.S.S.N. 09/833,407
Transmittal of IDS

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

A handwritten signature in cursive script, appearing to read "Clark G. Sullivan", is written over a horizontal line.

Clark G. Sullivan

Date: November 6, 2001

File No.: ATH113 (04676.105059)

Please type a plus sign (+) inside this box → ☐

PTO/SB-08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
JAN 18 2001
FBI CENTER 1600/2900

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) JAN 15 2002 Sheet <input type="checkbox"/> of <input type="checkbox"/> 3				Application Number	09/833,407
				Filing Date	April 11, 2001
				First Named Inventor	Luchoomun <i>et al.</i>
				Group Art Unit	1614
				Examiner Name	Not Assigned
				Attorney Docket Number	ATH113US (04676.105059)

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Cols, Lns, Where Relevant Passages/Figures Appear
		Number	Kind Code (if known)			
	AA	4,076,841		Wagner <i>et al.</i>	02/28/1978	
	AB	5,262,439		Parthasarathy	11/16/1993	
	AC	5,627,205		Regnier <i>et al.</i>	05/06/1997	
	AD	5,770,355		Brocia <i>et al.</i>	06/23/1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Date of Publication of Cited Document DD-MM-YYYY	Country	Pgs, Clms, Lns, Where Relv. Psgs/ Fig Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
	AE	WO	95/30415	A1	16.11.1995	PCT-US		
	AF	WO	97/26258	A1	24.07.1997	PCT-EPO		
	AG	WO	98/30255	A2	16.17.1998	PCT-US		
	AH	WO	98/51289	A2	19.11.1998	PCT-US		
	AI	WO	98/51662	A2	19.11.1998	PCT-US		
	AJ	WO	99/24400	A1	20.05.1909	PCT-US		
	AK	WO	00/26184	A1	11.05.2000	PCT-Germany		
	AL	WO	00/28332	A1	18.05.2000	PCT-US		
	AM	EPO	212 310	A2	04.03.1987	EPO-Germany		
	AN	EPO	254 272	A2	27.01.1988	EPO		
	AO	EPO	292 660	A2	30.11.1988	EPO		
	AP	EPO	348 203	A1	27.12.1989	Great Britain		
	AQ	EPO	418 648	A1	27.03.1991	EPO-Germany		
	AR	FR	2.130.975		10.11.1972	France		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



Approved for use through 10/31/2001. PTO/SB/08A (08-06)
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
JAN 18 2001
PCT CENTER 1500/2900

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/815,262
Filing Date	March 11, 2001
First Named Inventor	Meng <i>et al.</i>
Group Art Unit	1614
Examiner Name	Not Assigned
Attorney Docket Number	04676.105055

Sheet 1 of 3

FOREIGN PATENT DOCUMENTS (CONTINUED)

BA	FR	2.133.024	24.11.1972	France	
BB	FR	2.134.810	08.12.1972	France	
BC	FR	2.140.769	19.01.1973	France	
BD	FR	2.168.137	31.08.1973	France(Eng. Trans.)	✓

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	BE	CHEMICAL ABSTRACT, DATABASE CHEMABS 'Online!', CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, STN, Accession No. 127:75973, XP002115597, see abstract; RN 1706-68-9 & V.Z. LANKIN ET AL.: DOKL. AKAD. NAUK, V. 351, No. 4, 1996, pgs. 554-557.	
	BF	CHEMICAL ABSTRACT, DATABASE CHEMABS 'Online!', CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, STN, CAPLUS Accession No. 1970:445047, XP002124423, see abstract; RN 27428-10-0, 27428-13-3, 27428-14-4, 27428-15-5, 27428-16-6, 27428-17-7, 27428-18-8, 27428-19-9 & M. B. NEUWORTH ET AL.: J. MED. CHEM., V. 13, No. 4, 1970, pp. 722-725.	
	BG	CHEMICAL ABSTRACT, DATABASE CHEMABS 'Online!', CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, STN, CAPLUS Accession No. 1986:28675, XP002124424, see abstract; RN 99661-86-6, 99661-87-7, 27466-44-0 & CHEMICAL ABSTRACTS, Vol. 104, No. 5, 3 February 1986 (1986-02-03), Columbus, Ohio, US; Abstract No. 28675, abstract & P. DE MEGLIO ET AL.: FARMACO, ED. SCI., Vol. 40, No. 11, 1985, pages 833-844.	✓
	BH	COMINACINI et al., "Antioxidants Inhibit the Expression of Intercellular Cell Adhesion molecule-1 and Vascular Cell Adhesion Molecule-1 Induced by Oxidized LDL on Human Umbilical Vein Endothelial Cells," <u>Free Radical Biology & Medicine</u> , Vol. 22, Nos. 1/2, pp. 117-127, 1997.	
	BI	FELDMAN, Davis, et al., "The In Vitro and Ex Vivo Antioxidant Properties, and Hypolipidemic Activity of CGP 2881," <u>Atherosclerosis</u> , 28 December 1998, Vol. 144, pp. 343-355.	
	BJ	FRUEBIS, Joachim, "A Comparison of the Antiatherogenic Effects of Probucol and of a Structural Analogue of Probucol in Low Density Lipoprotein Receptor-deficient Rabbits," <u>The American Society for clinical Investigation, Inc.</u> , July 1994, Vol. 94, pp. 392-398.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside
this box



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

of

3

Complete if Known

Application Number	09/815,262
Filing Date	March 11, 2001
First Named Inventor	Meng <i>et al.</i>
Group Art Unit	1614
Examiner Name	Not Assigned
Attorney Docket Number	04676.105055

RECEIVED
JAN 18 2001
TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS (CONTINUED)

CA	MAO et al., "Antioxidant Activity of Probucol and Its Analogues in Hypercholesterolemic Watanabe Rabbits," <u>Journal of Medicinal Chemistry</u> , January 1991, Vol. 34, No. 1, pp. 298-302.
CB	MAO et al. "Attenuation of Atherosclerosis in a Modified Strain of Hypercholesterolemic Watanabe Rabbits with Use of a Probucol Analogue (MDL29,311) That Does Not Lower Serum Cholesterol," <u>Arteriosclerosis and Thrombosis</u> , September/October 1991, Vol. 11, No. 5, pp. 1266-1275.
CC	RAMASAMY, Santhini et al., "Modulation of Expression of Endothelial Nitric Oxide Synthase by Nordihydroguaiaretic Acid, a Phenolic Antioxidant in Cultured Endothelial Cells," <u>Molecular Pharmacology</u> , 5 April 1999, Vol. 56, pp. 116-123.

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.